子宫内膜间质肉瘤
医学
淋巴结切除术
平滑肌肉瘤
肉瘤
阶段(地层学)
子宫内膜癌
子宫肉瘤
子宫切除术
淋巴结
妇科
肿瘤科
癌症
内科学
放射科
病理
生物
古生物学
作者
Dimitrios Nasioudis,Spyridon A. Mastroyannis,Nawar Latif,Emily Ko,Ashley Haggerty,Sarah H. Kim,Mark A. Morgan,Robert Giuntoli
标识
DOI:10.1016/j.suronc.2021.101589
摘要
Investigate the role of lymphadenectomy for patients with apparent stage I uterine sarcoma.The National Cancer Database was accessed and patients without a history of another tumor diagnosed between 2004 and 2015 with an apparent early stage leiomyosarcoma, adenosarcoma, low-grade endometrial stromal and high-grade endometrial stromal/undifferentiated sarcoma who underwent hysterectomy with or without lymphadenectomy were identified. Overall survival was assessed after stratification by histology with the log-rank test while Cox models were constructed to control for confounders.A total of 6412 patients with apparent early stage uterine sarcoma who underwent hysterectomy were identified; 2820 (44%) underwent lymphadenectomy. Rate of lymph node metastasis was 3.4% (42/1250) for patients with leiomyosarcoma, 2.3% (19/826) for those with adenosarcoma, 4.5% (21/463) for patients with low-grade endometrial stromal sarcoma and 7.9% (22/280) for those with high-grade endometrial stromal/undifferentiated sarcoma, p < 0.001. After controlling for confounders lymphadenectomy was not associated with better survival for patients with adenosarcoma (HR: 0.92, 95% CI: 0.73, 1.17), or low-grade endometrial stromal sarcoma (HR: 1.17, 95% CI: 0.73, 1.87). Patients with leiomyosarcoma who underwent lymphadenectomy had worse survival (HR: 1.15, 95% CI: 1.03, 1.28). Patients with high-grade endometrial stromal/undifferentiated sarcoma who underwent lymphadenectomy had better survival (HR: 0.66, 95% CI: 0.48, 0.89).Incidence of lymph node metastasis in apparent early stage uterine sarcoma is rare while the performance of lymphadenectomy was not associated with a clear survival benefit for all histologic subtypes except high-grade endometrial stromal/undifferentiated sarcoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI